BASECARE-B's Embryo Culture Medium Receives Chinese Regulatory Approval

Stock News
02/26

BASECARE-B (02170) has announced that its Geri embryo culture medium, a product within the Gems embryo culture series, received a Class III Medical Device Registration Certificate from China's National Medical Products Administration on February 25, 2026. Prior to this approval, the Geri embryo culture medium had already obtained certifications from European CE, the U.S. Food and Drug Administration, and Australia's Therapeutic Goods Administration. The core technology for this product originates from the Sydney IVF Centre.

Integrated with the Geri time-lapse incubator and an AI embryo evaluation system, the Geri embryo culture medium has now entered clinical practice in China. It addresses challenges in embryo cultivation for older patients through its two core advantages: an antioxidant formulation and a stable osmotic pressure environment. The technical focus of the Geri culture medium lies in providing a systematic solution tailored to the reproductive difficulties faced by older patients. Its "triple antioxidant protection network" effectively mitigates oxidative stress in embryos from older patients. Combined with pre-added human serum albumin and long-term stability, it significantly simplifies laboratory procedures and ensures a consistent culture environment.

International clinical validation indicates that when used with the Geri time-lapse incubator and AI embryo evaluation system, this culture medium can notably increase the rates of high-quality blastocyst formation and clinical pregnancy, offering robust support for advanced-age fertility. This approval marks a critical step for the company in transitioning from technology introduction to localized production, filling a gap in domestically produced high-end assisted reproductive consumables. BASECARE-B has become the first Chinese company to hold four major international certifications: FDA, CE, TGA, and NMPA. Leveraging its core PGT technology and in-house supply capacity for consumables, the company now serves the vast majority of licensed PGT institutions across China and has established dozens of localized laboratories, creating a continuously evolving ecosystem barrier.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10